As FY25 results reveal a mixed year for Pfizer, the company is looking to turn its fortunes around with newly acquired Metsera obesity assets.

Despite posting strong results in the final quarter of 2025, MSD (Merck & Co) has cut its 2026 guidance more than analysts ...

SanegeneBio has entered into a $1.5bn global licensing agreement with Genentech, part of the Roche Group, for one of its RNAi ...

Aquestive has received a CRL from the FDA regarding its NDA for Anaphylm, which aims to treat type I allergic reactions in patients weighing 30kg or more.

Kyowa Kirin will now file for rocatinlimab’s US approval in atopic dermatitis (AD), which was once Amgen’s most late-stage pipeline candidate.

Historically a steel production hub, Lehigh Valley will now help manufacture Lilly’s weight loss drug hopeful retatrutide.

Johnson & Johnson has received a positive opinion from the EMA CHMP and recommended an indication extension for Akeega .

The California Institute for Regenerative Medicine has approved the RAPID funding programme, setting aside $100m over two ...

The US Food and Drug Administration (FDA) will start accepting applications for the new PreCheck scheme that will streamline ...

Sanofi's sales grew 9.9% YoY – driven by a diverse range of portfolio classics and new launches across immunology, oncology and rare disease.